ARVN Live signals | Maximize Profits with Getagraph.com

BUY 120836 min ago

@ $49.33

Issued: 14 Feb 2024 @ 15:32

Return: -33.81%

Previous signal: Feb 14 - 10:03

Previous signal: Sell

Return: 2.08 %

Live Chart Being Loaded With Signals

Commentary (8 May 2024 @ 14:28):

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins...

Stats
Today's Volume	327 660
Average Volume	748 745
Market Cap	2.23B
EPS	$-2.53 ( 2024-05-03 )
Next earnings date	( $-1.410 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.93
ATR14	$0.0480 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Berkowitz Noah	Buy	93 879	Stock Option (right to buy)
2024-03-18	Berkowitz Noah	Buy	63 452	Common Stock
2024-03-18	Berkowitz Noah	Buy	0
2024-02-29	Teel Randy	Sell	0	Common Stock
2024-02-29	Teel Randy	Sell	0	Common Stock

INSIDER POWER
45.35
Last 95 transactions
Buy: 1 590 588 \| Sell: 490 115

Volume Correlation

Long: -0.09 (neutral)

Short: 0.05 (neutral)

Signal:(55.571) Neutral

Arvinas Inc Correlation

10 Most Positive Correlations
WSC	0.911
XMTR	0.905
PRSO	0.902
TRS	0.899
GMBL	0.898
SELB	0.898
SPTN	0.898
AMNB	0.897
ROIC	0.896
ESSA	0.895

10 Most Negative Correlations
TVTY	-0.902
WLTW	-0.898
BTAQ	-0.897
SGEN	-0.893
USLM	-0.891
GPACU	-0.887
FRSG	-0.885
NVSA	-0.883
GVCI	-0.883
MLAI	-0.881

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arvinas Inc Correlation - Currency/Commodity

-0.81
( strong negative )

-0.82
( strong negative )

-0.83
( strong negative )

-0.69
( moderate negative )

0.62
( weak )

-0.24
( neutral )

Arvinas Inc Financials

Annual	2023
Revenue:	$78.50M
Gross Profit:	$71.80M (91.46 %)
EPS:	$-6.62

FY	2023
Revenue:	$78.50M
Gross Profit:	$71.80M (91.46 %)
EPS:	$-6.62

FY	2022
Revenue:	$131.40M
Gross Profit:	$123.20M (93.76 %)
EPS:	$-5.11

FY	2021
Revenue:	$46.00M
Gross Profit:	$46.00M (100.00 %)
EPS:	$-3.82

Financial Reports:

No articles found.

Arvinas Inc

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.